NCT05218005Completed
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
The Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) Study
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact patient care and outcomes. The study will recruit patients admitted to hospital with an acute coronary syndrome, and research-based genetic testing will be conducted for known FH-causing genetic variants. The results will be returned to the patients' treating physicians. The primary endpoint will be the number of patients with a new diagnosis of definite FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL cholesterol level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 15 months after the index acute coronary syndrome.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 140 (actual)
- First submitted
- 19 Jan 2022
- Start date
- 1 Jan 2022
- Primary completion date
- 17 Jun 2024
- Lead sponsor
- University of British Columbia
- NCT number
- NCT05218005
What you commit to
- Study type: Interventional
- Participants enrolled: 140
- From 1 Jan 2022 to the primary completion date, 17 Jun 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Age \<60 years
- AND
- Admitted to an acute cardiac unit with either:
- A ST elevation myocardial infarction (STEMI), or
- A non-ST elevation myocardial infarction (NSTEMI)
- AND
- Maximum lipid level at the time of admission or during the prior 1 year of
- LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, or
- LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, or
- Non-HDL-C ≥4.6 mmol/L (177 mg/dL)
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St Pauls Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
| Vancouver General Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.